NCT00053677View on ClinicalTrials.gov

Drug Treatment for Pathologic Gambling Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Gambling
Interventions
DRUG

Naltrexone

For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.

DRUG

Placebo

For subjects who were randomly assigned to placebo.

Trial Locations (1)

55454

University of Minnesota Medical School, Minneapolis

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Chicago

OTHER

NCT00053677 - Drug Treatment for Pathologic Gambling Disorder | Biotech Hunter | Biotech Hunter